Monitor this situation.

Unsubscribe anytime.

[SITUATION] · [QUIET] · [BUSINESS]

2 clusters · 8 sources · 8 days · First seen 18 days ago · Last updated 11 days ago

Revier Therapeutics launch and funding

Overview

Heidelberg-based biotechnology company Revier Therapeutics has officially launched following a €6 million seed financing round. The funding, led by the KHAN Technology Transfer Fund II with participation from High-Tech Gründerfonds, VORNvc, and private investors, is intended to support the development of selective class IIa histone deacetylase (HDAC) inhibitors.

The company’s research, based on cardiovascular studies from Heidelberg University, focuses on treating cardiometabolic diseases. Its preclinical pipeline includes programs targeting atherosclerotic cardiovascular disease (ASCVD) and heart failure with preserved ejection fraction (HFpEF). The company aims to develop small molecules that target disease-associated enzymatic activity while avoiding the dose-limiting toxicities associated with broader inhibitors.

Entities

Revier Therapeutics · High-Tech Gründerfonds · KHAN Technology Transfer Fund II · Heidelberg University · Johannes Backs

Timeline

11 days ago

[BUSINESS] 5 sources
Revier Therapeutics launches with €6 million funding
German biotech firm Revier Therapeutics has launched with €6 million in funding.
18 days ago

[BUSINESS] 3 sources
Revier Therapeutics raises €6M for cardiometabolic drug development
Revier Therapeutics has raised €6 million in seed funding to develop selective class IIa HDAC inhibitors for cardiometabolic diseases, including heart failure and atherosclerosis.

Sources

a1retailmagazine.com · cumberland.gov.uk · european-biotechnology.com · goingpublic.de · htworld.co.uk · opticien-presse.fr · schauspielernews.de · startbase.de